Administration of OKT3 as a two-hour infusion does not attenuate first-dose side effects.
Kandaswamy
R
R
Kamps
M
M
Matas
A J
AJ
D000328:Adult; D004334:Drug Administration Schedule; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3